<span identification=”midArticle_start”/> (Reuters) – Ocular Therapeutix Inc says itslead eye drug failed to satisfy probably the most primary objectives in a secondlate-stage find out about.
<span identification=”midArticle_0″/>The drug, OTX-DP, was once efficient in decreasing ache in patientswho had cataract surgical operation, however failed to cut back the inflammationin the eyes, the corporate stated.
<span identity=”midArticle_1″/>Each endpoints wanted to be met for the trial to beconsidered a hit, Ocular Therapeutix stated.
<span identification=”midArticle_2″/>Buying and selling within the firm’s inventory used to be halted on the Nasdaq.
<span identity=”midArticle_3″/>Ocular Therapeutix mentioned in March that the drug lowered painand irritation in sufferers in a primary late-stage trial. (Reporting by using Rosmi Shaji in Bengaluru; Modifying with the aid of SavioD’Souza)
<span identity=”midArticle_4″/>
The post Ocular Therapeutix eye drug misses a primary purpose in 2d late-stage learn about appeared first on Smart Health Shop Blog.
via Smart Health Shop Blog http://ift.tt/1JhsHhg
No comments:
Post a Comment